{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-105453","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2026-10-01T11:57:57+00:00","discovered_at":"2026-10-01T12:00:00.269001+00:00","generated_at":"2026-10-12T14:15:53.094175+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nektar's rezpegaldesleukin shows durable hair regrowth in alopecia areata; Phase 3 ZENITH AA to start early 2027","bullets":["Alopecia areata: SALT Score ≤20 response maintained in 75% (6/8) at 4 months off treatment and 63% (5/8) at 6 months; SALT ≤10 deepened from 7% at Week 52 to 19% off treatment.","REZOLVE-AA: Week 36-52, 29% low dose (18 µg/kg) and 31% high dose (24 µg/kg) achieved new SALT ≤20 vs none on placebo; 850-patient Phase 3 ZENITH AA starts early 2027.","Atopic dermatitis REZOLVE-AD: maintenance Q4W raised EASI-100 from 4% to 22%; Q12W from 9% to 18%; among prior responders, Q4W 6% to 30%, Q12W 14% to 27%.","Third Phase 3 ZENITH AD study initiated in treatment-experienced atopic dermatitis; safety through 52 weeks favorable and consistent with prior profile."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-105453","json":"https://secwatch.observer/filing/0001213900-26-105453.json","markdown":"https://secwatch.observer/filing/0001213900-26-105453.md","text":"https://secwatch.observer/filing/0001213900-26-105453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390026105453/0001213900-26-105453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390026105453/ea0307306-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:15:53.094175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}